Mankind Pharma inks pact with Takeda to market Vonoprazan

18 Jul 2024 , 10:48 AM

Mankind Pharma announced on Tuesday that it has signed into a non-exclusive patent licensing deal with Japanese drugmaker Takeda to commercialise the latter’s Vonoprazan in India.

The deal permits Mankind Pharma to market a unique medicine for the treatment of Gastroesophageal Reflux Disease (GERD) under its trademark.

Vonoprazan is a potassium-competitive acid blocker (P-CAB) used to treat acid-related conditions, such as Gastroesophageal Reflux Disease (GERD).

The medication is useful in treating erosive oesophagitis, gastric ulcers, duodenal ulcers, peptic ulcers, gastro-oesophageal reflux, reflux oesophagitis, and Helicobacter pylori infection.

Mankind Pharma is prioritising in-licensing agreements to introduce novel medications to the domestic formulation market.

The Delhi-based startup has signed in-licensing arrangements with Novartis for the heart failure treatment Neptaz. In May 2024, it secured a license agreement with AstraZeneca to commercialise the inhaled corticosteroid medication Symbicort in India.

Indian medicine businesses, such as Mankind, use in-licensing to promote and distribute global corporations’ novel drugs in the Indian market. They pay a royalty on sales. MNCs utilise licensing to enhance their product access in the Indian market by leveraging local enterprises’ pan-India sales networks.

“By introducing Vonoprazan, we hope to address a significant medical need and improve the quality of life for those suffering from acid-related illnesses by providing a new and advanced option for managing acid-related disorders, potentially leading to better health outcomes and quality of life,” said M Ramesh, EVP, Global Business Development, Mankind Pharma.

At around 10.43 AM, Mankind Pharma was trading 0.62% higher at ₹2,128.75 per piece, against the previous close of ₹2,115.70 on NSE. The counter touched an intraday high and low of ₹2,140, and ₹2,116.30, respectively.

For feedback and suggestions, write to us at [e-mail]